RecruitingPhase 3NCT05970783

A Study of Jincaopian Tablets on Chronic Pelvic Pain After Pelvic Inflammatory Disease

A Multicenter, Randomized, Double-blind, Dose-parallel, Placebo-controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of Jincaopian Tablets in Subjects with Chronic Pelvic Pain After Pelvic Inflammatory Disease

Sponsor

Beijing Konruns Pharmaceutical Co., Ltd.

Enrollment

414 participants

Start Date

Nov 8, 2022

Study Type

INTERVENTIONAL

Conditions

Chronic pelvic pain

Summary

The objective of this phase III trial to evaluate the efficacy and safety of Jincaopian Tablets in the treatment of subjects with chronic pelvic pain after pelvic inflammatory disease

Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 50 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Jincaopian Tablets and Placebo for people with chronic pelvic pain. The study is currently recruiting participants at 1 location. People eligible for this study include women aged 18 Years to 50 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGJincaopian Tablets

Jincaopian Tablets 0.2g tid p.o.

OTHERPlacebo

Placebo 0.2g tid p.o.

Locations(1)

Beijing Hospital of Traditional Chinese Medicine affiliated to Capital Medical University

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05970783

Related Trials

Pelvic Floor Muscle Function and Endometriosis-Related Pelvic Pain

NCT077131081 location

Evaluation of the Analgesic Effect of Intramyometrial Botulinum Toxin Injection Via Hysteroscopy in Pelvic Pain Suggestive of Dysmenorrhea

NCT069952878 locations